Skip to content
Artwork for Innovating Clinical Trials
Innovating Clinical Trials · May 21 · 13 min

Ep 2.23: Jill Fikowski on Why Participants Drop Out and What to Do About It (3/3)

In the final episode of our three-part series with Jill Fikowski, founder and CEO of Changemark Research + Evaluation, we get into one of the most persistent problems in clinical research: retention. Jill unpacks why participants drop out and it's rarely what sponsors assume. From there, we get into the pressure that lands on research coordinators when enrollment is behind, the practices that pressure produces. We also look at what happens after the last visit particularly in psychedelic trials and whether researchers have a responsibility that doesn't end when the database closes. Retention problems, Jill argues, are almost always inception problems. And solving them starts with a question most teams never ask. Part 3 of 3.

0:00-13:59

transcript

No transcript — this publisher did not publish one.

show notes

In the final episode of our three-part series with Jill Fikowski, founder and CEO of Changemark Research + Evaluation, we get into one of the most persistent problems in clinical research: retention.

Jill unpacks why participants drop out and it's rarely what sponsors assume.  From there, we get into the pressure that lands on research coordinators when enrollment is behind, the practices that pressure produces. We also look at what happens after the last visit particularly in psychedelic trials and whether researchers have a responsibility that doesn't end when the database closes.

Retention problems, Jill argues, are almost always inception problems. And solving them starts with a question most teams never ask.

Part 3 of 3.